Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 20/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875066 | 0.69 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1376647 | 0.69 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL4592207 | 0.67 | GABRG2 (0.76) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3882552 | 0.66 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3876116 | 0.65 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2431184 | 0.64 | GABRG2 (0.84) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1376589 | 0.63 | GABRG2 (0.69) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL4593227 | 0.62 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2431006 | 0.62 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1377824 | 0.62 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1807432-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | GABRG2 24/4885GABRB3 10/4885GABRA5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.